PF-07328948 + clarithromycin

PF-07328948 + clarithromycin is a drug combination used in clinical pharmacology studies to evaluate the pharmacokinetic interaction between PF-07328948, an investigational small molecule inhibitor of Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4), and clarithromycin, a potent CYP3A4 inhibitor. PF-07328948 is being developed by Pfizer for the treatment of inflammatory conditions, including potentially cardiovascular or metabolic diseases where MAP4K4 signaling plays a role in tissue injury or inflammation. Clarithromycin is a macrolide antibiotic that serves as a clinical probe to determine if PF-07328948 is a substrate for CYP3A4-mediated metabolism, helping to characterize the drug's metabolic profile and potential for drug-drug interactions.

Other names

PF-07328948 and clarithromycinPF07328948 and clarithromycinPF 07328948 and clarithromycin